Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose
Journal
Investigational New Drugs
Journal Volume
33
Journal Issue
4
Pages
942-953
Date Issued
2015
Author(s)
Venkatakrishnan K.
Kim T.M.
Thye L.S.
Chng W.J.
Ma B.
Chen M.H.
Zhou X.
Liu H.
Kelly V.
Kim W.S.
SDGs
Publisher
Springer New York LLC
Type
journal article